Auxiliary Medicinal Product - Luteinizing hormone-releasing hormone (LHRH) analogues clinical trials

Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.

This study is for people with advanced ER+/HER2- breast cancer with an ESR1 gene change, whose cancer has grown despite previous treatments. It tests a new drug called elacestrant alongside an existing one, everolimus, to see if this combination works better at stopping the cancer from growing.